Literature DB >> 17049251

Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.

Tomoko Nakata1, Takeshi Yamada, Sayaka Taji, Hirofumi Ohishi, Shun-Ichi Wada, Harukuni Tokuda, Kazuo Sakuma, Reiko Tanaka.   

Abstract

Two new lanostane-type triterpenoids, inonotsuoxides A (1) and B (2) along with three known lanostane-type triterpenoids, inotodiol (3), trametenolic acid (4), and lanosterol (5), were isolated from the sclerotia of Inonotus obliquus (Pers.: Fr.) (Japanese name: Kabanoanakake) (Russian name: Chaga). Their structures were determined to be 22R,25-epoxylanost-8-ene-3beta,24S-diol (1) and 22S,25-epoxylanost-8-ene-3beta,24S-diol (2) on the basis of spectral data including single crystal X-ray analysis. These compounds except for 2 were tested for their inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), as a test for potential cancer chemopreventive agents. The most abundant triterpene, inotodiol (3), was investigated for the inhibitory effect in a two-stage carcinogenesis test on mouse skin using 7,12-dimethylbenz[a]anthracene (DMBA) as an initiator and TPA as a promoter. Compound 3 was found to exhibit the potent anti-tumor promoting activity in the in vivo carcinogenesis test.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17049251     DOI: 10.1016/j.bmc.2006.09.064

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  11 in total

Review 1.  Progress of research on Inonotus obliquus.

Authors:  Xiu-hong Zhong; Kuang Ren; Shi-jie Lu; Shu-yan Yang; Dong-zhi Sun
Journal:  Chin J Integr Med       Date:  2009-04-29       Impact factor: 1.978

Review 2.  Spatial and temporal control of fungal natural product synthesis.

Authors:  Fang Yun Lim; Nancy P Keller
Journal:  Nat Prod Rep       Date:  2014-10       Impact factor: 13.423

3.  Anticancer activity of subfractions containing pure compounds of Chaga mushroom (Inonotus obliquus) extract in human cancer cells and in Balbc/c mice bearing Sarcoma-180 cells.

Authors:  Mi Ja Chung; Cha-Kwon Chung; Yoonhwa Jeong; Seung-Shi Ham
Journal:  Nutr Res Pract       Date:  2010-06-29       Impact factor: 1.926

4.  Chemical constituents from Inonotus obliquus and their antitumor activities.

Authors:  Fenqin Zhao; Guiyang Xia; Lixia Chen; Junli Zhao; Zhanfang Xie; Feng Qiu; Guang Han
Journal:  J Nat Med       Date:  2016-05-14       Impact factor: 2.343

Review 5.  Mushrooms: an emerging resource for therapeutic terpenoids.

Authors:  Adhiraj Dasgupta; Krishnendu Acharya
Journal:  3 Biotech       Date:  2019-09-24       Impact factor: 2.406

6.  Ethanol extract of Innotus obliquus (Chaga mushroom) induces G1 cell cycle arrest in HT-29 human colon cancer cells.

Authors:  Hyun Sook Lee; Eun Ji Kim; Sun Hyo Kim
Journal:  Nutr Res Pract       Date:  2015-03-12       Impact factor: 1.926

Review 7.  Medicinal Properties and Bioactive Compounds from Wild Mushrooms Native to North America.

Authors:  Mehreen Zeb; Chow H Lee
Journal:  Molecules       Date:  2021-01-06       Impact factor: 4.411

8.  Continuous intake of the Chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice.

Authors:  Satoru Arata; Jun Watanabe; Masako Maeda; Masato Yamamoto; Hideto Matsuhashi; Mamiko Mochizuki; Nobuyuki Kagami; Kazuho Honda; Masahiro Inagaki
Journal:  Heliyon       Date:  2016-05-12

Review 9.  Medicinal mushrooms as an attractive new source of natural compounds for future cancer therapy.

Authors:  Artem Blagodatski; Margarita Yatsunskaya; Valeriia Mikhailova; Vladlena Tiasto; Alexander Kagansky; Vladimir L Katanaev
Journal:  Oncotarget       Date:  2018-06-26

10.  Supercritical CO2 Extraction of Triterpenoids from Chaga Sterile Conk of Inonotus obliquus.

Authors:  Nghia Huynh; Gabriele Beltrame; Marko Tarvainen; Jukka-Pekka Suomela; Baoru Yang
Journal:  Molecules       Date:  2022-03-14       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.